What is the appropriate dosing regimen for Invega Sustenna (paliperidone palmitate) in an adult patient with schizophrenia who has not previously received paliperidone?

Invega Sustenna Dosing

For treatment-naïve patients with schizophrenia, initiate Invega Sustenna with 234 mg on day 1 and 156 mg on day 8, both administered into the deltoid muscle, followed by monthly maintenance doses of 39-234 mg (recommended 117 mg) starting 5 weeks after the first injection. 1

Pre-Treatment Considerations

Before initiating Invega Sustenna, establish tolerability with oral paliperidone or oral risperidone in patients who have never taken these medications 1. This is critical to avoid committing patients to a long-acting formulation if they cannot tolerate the medication.

Initiation Regimen

The FDA-approved loading strategy is designed to achieve therapeutic plasma levels rapidly without oral supplementation:

• Day 1: 234 mg deltoid injection
• Day 8: 156 mg deltoid injection (±4 days window acceptable)
• Day 36 (5 weeks after first dose): Begin monthly maintenance dosing

Needle Selection for Deltoid Injections

Weight-based needle selection is mandatory for deltoid administration 1:

• <90 kg: 1-inch, 23-gauge needle
• ≥90 kg: 1½-inch, 22-gauge needle

This dosing regimen achieves target plasma levels by day 8, providing rapid symptom control 2. The initiation doses are well-tolerated even in recently diagnosed patients, with injection site pain (5.5%), agitation (4.6%), and headache (3.7%) being the most common early adverse events 3.

Maintenance Dosing

Starting at week 5 (day 36), administer monthly injections:

• Schizophrenia: 39-234 mg range; recommended dose is 117 mg 1
• Schizoaffective disorder: 78-234 mg range 1
• Injection site: Either deltoid (weight-adjusted needle) or gluteal (1½-inch, 22-gauge needle for all patients)
• Timing flexibility: ±7 days from monthly target date 1

Alternate between injection sites (left/right deltoid or left/right gluteal) to minimize local reactions 1.

Dose Adjustments

Monthly dose adjustments are permitted, but the prolonged-release characteristics mean full effects may not be evident for several months 1. Individualize based on:

• Efficacy: Assess symptom control at 4 weeks per current guidelines 4
• Tolerability: Monitor for extrapyramidal symptoms, metabolic effects, and sedation
• Pharmacokinetic factors: Age, renal function (adjust if CrCl 50-80 mL/min), ethnicity, concomitant medications 4

Managing Missed Doses

Missed Second Initiation Dose (Day 8)

The approach depends on elapsed time since the first injection 1:

<4 weeks:

• Give 156 mg deltoid immediately
• Give 117 mg (deltoid or gluteal) at week 5 from first injection
• Resume monthly dosing

4-7 weeks:

• Give 156 mg deltoid immediately
• Give second 156 mg deltoid 1 week later
• Resume monthly dosing

>7 weeks: Restart full initiation (234 mg day 1,156 mg day 8)

Missed Maintenance Dose

4-6 weeks since last injection: Resume at previous dose immediately, continue monthly

>6 weeks to 6 months:

• If stabilized on <234 mg: Resume same dose with two deltoid injections 1 week apart, then monthly
• If stabilized on 234 mg: Give 156 mg twice (1 week apart), then resume monthly at 234 mg

>6 months: Restart full initiation regimen 1

Special Populations

Renal impairment (CrCl 50-80 mL/min): Reduce initiation to 156 mg day 1,117 mg day 8; maintenance 39-156 mg 1

Hepatic impairment: No adjustment needed for mild-moderate; no data for severe 5

Elderly: Same dosing if renal function normal; adjust for age-related CrCl decline 5

Switching from Other Antipsychotics

From oral antipsychotics: Initiate Invega Sustenna the day after discontinuing oral medication 5

From other LAIs: Give first Invega Sustenna dose when next LAI injection would be due, using standard initiation regimen 5

Critical Safety Monitoring

While dosing, monitor for:

• Metabolic effects: Weight, glucose, lipids (offer metformin with significant weight gain per guidelines 4)
• Extrapyramidal symptoms: Akathisia shows dose-relationship 1
• Hyperprolactinemia: Dose-related effect 1
• Injection site reactions: Most common early adverse event (7.6%) 2
• QT prolongation, orthostatic hypotension, falls 1

The 2025 INTEGRATE guidelines position paliperidone (including Invega Sustenna) as a second-line option after D2 partial agonist failure, alongside risperidone, amisulpride, or olanzapine with metabolic mitigation 4.